2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Omics Technologies, Serologic Tests, Bioinformatics, Profiling, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Women’s Health, Biological Processes, Apoptosis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Indolent Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Animal Model
PAPER

2983 Transcriptomic analysis reveals two distinct subgroups of HHV8-associated multicentric castleman disease

Samantha Beck, BS, Sophia Maharry Roush, PhD2, Marriam Mponda, MBBs3, Edwards Kasonkanji, MPH4, Tamiwe Tomoka, MBBS5, Yuri Fedoriw, MD6, Matthew Scott Painschab, MD7
1 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
2 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
3 Kamuzu Central Hospital, Lilongwe, Malawi, UNC Project-Malawi, Lilongwe, Malawi
4 Kamuzu Central Hospital, Lilongwe, Malawi, UNC Project-Malawi, Lilongwe, Malawi
5 Kamuzu Central Hospital, Lilongwe, Malawi, UNC Project-Malawi, Lilongwe, Malawi
6 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States, UNC Project-Malawi, Lilongwe, Malawi, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
7 Indiana University Health, Indianapolish, Indiana, United States, UNC Project-Malawi, Lilongwe, Malawi

Introduction: Human herpesvirus 8-associated multicentric Castleman disease (HHV8-MCD) is a hematologic disorder that arises most commonly in people living with HIV (PLWH). If treated with chemotherapy alone, mortality is high and response is heterogeneous; outcomes are better with rituximab though not all patients remain in remission. Comprehensive data on gene expression profiling from HHV8-MCD has not, to our knowledge, been previously reported. Given that this disease frequently occurs in PLWH well controlled on ART a deep understanding of the underlying pathology is critical to improve outcomes for HHV8-MCD in all parts of the world.

Methods: HHV8-MCD patients (N=22) were enrolled between 2014 and 2018 as part of the Kamuzu Central Hospital Lymphoma Study in Lilongwe, Malawi; all had histologically confirmed de novo HHV8-MCD and were HIV-infected. All patients received chemotherapy as first-line treatment (CVP or etoposide), and some received rituximab in subsequent lines of therapy by compassionate use. All participants continued or initiated ART. Benign controls (N=15) were obtained from University of North Carolina and included n=5 HIV+ lymphadenitis and n=10 benign/reactive lymph nodes, n=1 of which was HIV-negative. Whole-transcriptome RNA sequencing was conducted on formalin-fixed, paraffin-embedded tissue samples. Genes with a median count less than 5 across all samples were removed. Downstream clustering of the MCD samples was achieved using the median-centered counts of the top 10% most variable genes and ConcensusClusterPlus. Cell type proportions were estimated using the default settings on CIBERSORTx and transcripts per million counts. Viral load estimates were generated by VirDetect and VIRTUS.

Results: HHV8-MCD participants in our cohort had a median age of 39.5 years (range 27-57), and seven (32%) were female. The controls had a median age of 44 years (range 22-53), and nine (60%) were female. Benign controls had a higher median HIV RNA viral load of 41,031 (range 112-839,638) versus HHV8-MCD (median 0, range 0-1,172,109; p-value = 0.002). HHV8-MCD cases had a higher Epstein-Barr virus and HHV8 viral RNA count. Differential gene expression identified 1,313 human genes altered in MCD compared to benign (|log2FC|>1 and adjp<0.05) where 651 genes were upregulated in MCD including IL10, CXCl13, CCND2 and enrichment of the MYC and MTORC1 pathways. Conversely, expression profiles of benign controls were enriched for interferon alpha and gamma pathways, including upregulation of FOXP3 and DAPK1. Benign controls also had an increased proportion of macrophages compared to MCD cases (M0: p=0.01, M1: p=0.1). Two distinct clusters of MCD cases were identified with similar clinical features, including HHV8 viral load; Cluster 1 trended towards worse overall survival by Kaplan-Meier methods. The clusters had 1,374 differentially expressed genes; 599 genes were upregulated in Cluster 1, including MYC, MIF, CCR7, LAG3 and GZMA/B, and 775 genes were upregulated in Cluster 2, including CXCL8, CXCL17, ILDR2, and IL1A. Many of the enriched pathways in Cluster 1 included metabolism pathways. Interestingly, while human IL6 expression did not differ by cluster, the HHV8 K2 gene, encoding viral IL6 (vIL6), had increased expression in Cluster 1 (log2FC=0.94, padj=0.07). Weighted gene co-expression network analysis (WGCNA) revealed 27 gene modules. The Green Module consisted of many immunoglobulin genes, was enriched for metabolism pathways, and associated with Cluster 1 and the proportion of plasma cells. Notably, the proportion of plasma cells did not differ between the two clusters, however Cluster 2 had an increase in the proportion of naïve B cells (p=0.05) and the total number of B cells (p=0.05) with an increase in IGH clonality (p=0.02).

Conclusion: Here we present one of the largest transcriptomic studies of HHV8-MCD to date. We characterized differences between HHV8-MCD and benign lymph nodes in PLWH, including an enrichment for MYC and MTORC1 signaling in HHV8-MCD. Additionally, we identified two distinct clusters in our HHV8-MCD cases with unique transcriptional programs. Cluster 1 had a lower, but more diverse, proportion of B cells, and an increased expression of vIL6 and immunoglobulin genes and is enriched for metabolic pathways. Taken together, this highlights a potential for metabolic reprogramming as a key feature underlying HHV8-MCD heterogeneity which may lead to future therapeutic targets.
Samantha Beck, BS: No relevant conflicts of interest to declare.